As part of the Ergomed Group, PrimeVigilance is pleased to share the Ergomed H1 2020 Trading Update.
21 May 2020.
PrimeVigilance, an Ergomed company, is pleased to announce its collaboration with Automation Anywhere and DataRobot to advance robotic processes and machine learning.
18 May 2020.
PrimeVigilance is pleased to share ERGOMED plc Press Release and to part of front against coronavirus
30 March 2020.
Our united front: PrimeVigilance response to Zagreb earthquake
23 March 2020.
Our United Front : Ergomed Plc Response to COVID-19
21 March 2020.
Guildford, UK – 18 March 2020: Ergomed plc (LSE: ERGO) (‘Ergomed’ or the ‘Company’), a company focused on providing specialised services to the pharmaceutical industry, today announces the initiation of a study of siltuximab, an interleukin (IL)-6 targeted monoclonal antibody, for the treatment of patients with COVID-19 who have developed serious respiratory complications (Siltuximab In Serious COVID-19; SISCO Study). The study is sponsored by the Papa Giovanni XXIII Hospital in Bergamo, Italy and supported by EUSA Pharma (EUSA) (see announcement below).
18 March 2020.
+44 (0)1483 307920
(+1) 781 703 5540
United Kingdom (Head Office)